Adrenoleukodystrophy Drugs Market in France - Manufacturing and Consumption, Outlook and Forecast 2020-2026

April 2020 | 91 pages | ID: A62F21DDCFF5EN
Market Monitor Global

Abstracts

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

This report contains market size and forecasts of Adrenoleukodystrophy Drugs in France, including the following market information:
France Adrenoleukodystrophy Drugs Market Revenue, 2015-2020, 2021-2026, ($ millions)
France Adrenoleukodystrophy Drugs Market Consumption, 2015-2020, 2021-2026, (K Units)
France Adrenoleukodystrophy Drugs Production Capacity, 2015-2020, 2021-2026, (K Units)
Top Five Competitors in France Adrenoleukodystrophy Drugs Market 2019 (%)
The global Adrenoleukodystrophy Drugs market was valued at 258.8 million in 2019 and is projected to reach US$ 456 million by 2026, at a CAGR of 15.2% during the forecast period. While the Adrenoleukodystrophy Drugs market size in France was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.
This report also analyses and evaluates the COVID-19 impact on Adrenoleukodystrophy Drugs production and consumption in France

Total Market by Segment:

France Adrenoleukodystrophy Drugs Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Units)
France Adrenoleukodystrophy Drugs Market Segment Percentages, By Type, 2019 (%)

• Hormone Replacement
• Transplant
• Others

France Adrenoleukodystrophy Drugs Market, By Application, 2015-2020, 2021-2026 ($ millions) & (K Units)
France Adrenoleukodystrophy Drugs Market Segment Percentages, By Application, 2019 (%)

• Childhood Cerebral ALD
• Adrenomyeloneuropathy (AMN)
• Addison-only
• Others

Competitor Analysis

The report also provides analysis of leading market participants including:
Total Adrenoleukodystrophy Drugs Market Competitors Revenues in France, by Players 2015-2020 (Estimated), ($ millions)
Total Adrenoleukodystrophy Drugs Market Competitors Revenues Share in France, by Players 2019 (%)
Total France Adrenoleukodystrophy Drugs Market Competitors Sales, by Players 2015-2020 (Estimated), (K Units)
Total France Adrenoleukodystrophy Drugs Market Competitors Sales Market Share by Players 2019 ($ millions)

Further, the report presents profiles of competitors in the market, including the following:

• Bluebird Bio Inc
• NeuroVia, Inc.
• Orpheris, Inc.
• Minoryx

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Adrenoleukodystrophy Drugs Market Definition
1.2 Market Segments
  1.2.1 Segment by Type
  1.2.2 Segment by Application
1.3 France Adrenoleukodystrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 COVID-19 IMPACT: FRANCE ADRENOLEUKODYSTROPHY DRUGS OVERALL MARKET SIZE

2.1 France Adrenoleukodystrophy Drugs Market Size: 2020 VS 2026
2.2 France Adrenoleukodystrophy Drugs Revenue, Prospects & Forecasts: 2015-2026
2.3 France Adrenoleukodystrophy Drugs Sales (Consumption): 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Adrenoleukodystrophy Drugs Players in France (including Foreign and Local Companies)
3.2 Top France Adrenoleukodystrophy Drugs Companies Ranked by Revenue
3.3 France Adrenoleukodystrophy Drugs Revenue by Companies (including Foreign and Local Companies)
3.4 France Adrenoleukodystrophy Drugs Sales by Companies (including Foreign and Local Companies)
3.5 France Adrenoleukodystrophy Drugs Price by Manufacturer (2015-2020)
3.6 Top 3 and Top 5 Adrenoleukodystrophy Drugs Companies in France, by Revenue in 2019
3.7 France Manufacturers Adrenoleukodystrophy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Players in France
  3.8.1 List of France Tier 1 Adrenoleukodystrophy Drugs Companies
  3.8.2 List of France Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - France Adrenoleukodystrophy Drugs Market Size Markets, 2020 & 2026
  4.1.2 Hormone Replacement
  4.1.3 Transplant
  4.1.4 Others
4.2 By Type - France Adrenoleukodystrophy Drugs Revenue & Forecasts
  4.2.1 By Type - France Adrenoleukodystrophy Drugs Revenue, 2015-2020
  4.2.2 By Type - France Adrenoleukodystrophy Drugs Revenue, 2021-2026
  4.2.3 By Type - France Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
4.3 By Type - France Adrenoleukodystrophy Drugs Sales & Forecasts
  4.3.1 By Type - France Adrenoleukodystrophy Drugs Sales, 2015-2020
  4.3.2 By Type - France Adrenoleukodystrophy Drugs Sales, 2021-2026
  4.3.3 By Type - France Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
4.4 By Type - France Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - France Adrenoleukodystrophy Drugs Market Size, 2020 & 2026
  5.1.2 Childhood Cerebral ALD
  5.1.3 Adrenomyeloneuropathy (AMN)
  5.1.4 Addison-only
  5.1.5 Others
5.2 By Application - France Adrenoleukodystrophy Drugs Revenue & Forecasts
  5.2.1 By Application - France Adrenoleukodystrophy Drugs Revenue, 2015-2020
  5.2.2 By Application - France Adrenoleukodystrophy Drugs Revenue, 2021-2026
  5.2.3 By Application - France Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
5.3 By Application - France Adrenoleukodystrophy Drugs Sales & Forecasts
  5.3.1 By Application - France Adrenoleukodystrophy Drugs Sales, 2015-2020
  5.3.2 By Application - France Adrenoleukodystrophy Drugs Sales, 2021-2026
  5.3.3 By Application - France Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
5.4 By Application - France Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026

6 MANUFACTURERS & BRANDS PROFILES

6.1 Bluebird Bio Inc
  6.1.1 Bluebird Bio Inc Corporate Summary
  6.1.2 Bluebird Bio Inc Business Overview
  6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Product Offerings
  6.1.4 Bluebird Bio Inc Sales and Revenue in France (2015-2020)
  6.1.5 Bluebird Bio Inc Key News
6.2 NeuroVia, Inc.
  6.2.1 NeuroVia, Inc. Corporate Summary
  6.2.2 NeuroVia, Inc. Business Overview
  6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
  6.2.4 NeuroVia, Inc. Sales and Revenue in France (2015-2020)
  6.2.5 NeuroVia, Inc. Key News
6.3 Orpheris, Inc.
  6.3.1 Orpheris, Inc. Corporate Summary
  6.3.2 Orpheris, Inc. Business Overview
  6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
  6.3.4 Orpheris, Inc. Sales and Revenue in France (2015-2020)
  6.3.5 Orpheris, Inc. Key News
6.4 Minoryx
  6.4.1 Minoryx Corporate Summary
  6.4.2 Minoryx Business Overview
  6.4.3 Minoryx Adrenoleukodystrophy Drugs Major Product Offerings
  6.4.4 Minoryx Sales and Revenue in France (2015-2020)
  6.4.5 Minoryx Key News
6.5 MedDay Pharmaceuticals
  6.5.1 MedDay Pharmaceuticals Corporate Summary
  6.5.2 MedDay Pharmaceuticals Business Overview
  6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Major Product Offerings
  6.5.4 MedDay Pharmaceuticals Sales and Revenue in France (2015-2020)
  6.5.5 MedDay Pharmaceuticals Key News

7 ADRENOLEUKODYSTROPHY DRUGS PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS

7.1 Adrenoleukodystrophy Drugs Production Capacity and Value in France, Situation Analysis and Prediction, 2015-2026
  7.1.1 France Adrenoleukodystrophy Drugs Production Capacity, 2015-2026
  7.1.2 France Adrenoleukodystrophy Drugs Production 2015-2026
  7.1.3 France Adrenoleukodystrophy Drugs Production Value 2015-2026
7.2 Key Local Adrenoleukodystrophy Drugs Manufacturers in France
  7.2.1 France Key Local Adrenoleukodystrophy Drugs Manufacturers Production Capacity
  7.2.2 France Key Local Adrenoleukodystrophy Drugs Manufacturers Production
  7.2.3 France Key Local Adrenoleukodystrophy Drugs Manufacturers Production Value
  7.2.4 The Proportion of Adrenoleukodystrophy Drugs Production Sold in France and Sold Other Than France by Manufacturers
7.3 Adrenoleukodystrophy Drugs Export and Import in France
  7.3.1 France Adrenoleukodystrophy Drugs Export Market
  7.3.2 France Adrenoleukodystrophy Drugs Source of Imports

8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

8.1 PESTLE Analysis for France Adrenoleukodystrophy Drugs Market
8.2 Market Opportunities & Trends
8.3 Market Drivers
8.4 Market Restraints

9 COVID-19 IMPACT ON ADRENOLEUKODYSTROPHY DRUGS SUPPLY CHAIN ANALYSIS

9.1 Supply Chain Analysis
9.2 Upstream Market Analysis
9.3 Downstream and Clients Market Analysis
9.4 Marketing Channels Analysis
  9.4.1 Marketing Channels
  9.4.2 Adrenoleukodystrophy Drugs Distributors and Sales Agents in France

10 CONCLUSION

11 APPENDIX

11.1 Note
11.2 Examples of Clients
11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Adrenoleukodystrophy Drugs in France
Table 2. Top Players in France, Ranking by Revenue (2019)
Table 3. France Adrenoleukodystrophy Drugs Revenue by Companies, (US$, Mn), 2015-2020
Table 4. France Adrenoleukodystrophy Drugs Revenue Share by Companies, 2015-2020
Table 5. France Adrenoleukodystrophy Drugs Sales by Companies, (K Units), 2015-2020
Table 6. France Adrenoleukodystrophy Drugs Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Adrenoleukodystrophy Drugs Price (2015-2020) (US$/Unit)
Table 8. France Manufacturers Adrenoleukodystrophy Drugs Product Type
Table 9. List of France Tier 1 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of France Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Adrenoleukodystrophy Drugs Revenue in France (US$, Mn), 2015-2020
Table 12. By Type - Adrenoleukodystrophy Drugs Revenue in France (US$, Mn), 2021-2026
Table 13. By Type - Adrenoleukodystrophy Drugs Sales in France (K Units), 2015-2020
Table 14. By Type - Adrenoleukodystrophy Drugs Sales in France (K Units), 2021-2026
Table 15. By Application - Adrenoleukodystrophy Drugs Revenue in France, (US$, Mn), 2015-2020
Table 16. By Application - Adrenoleukodystrophy Drugs Revenue in France, (US$, Mn), 2021-2026
Table 17. By Application - Adrenoleukodystrophy Drugs Sales in France, (K Units), 2015-2020
Table 18. By Application - Adrenoleukodystrophy Drugs Sales in France, (K Units), 2021-2026
Table 19. Bluebird Bio Inc Corporate Summary
Table 20. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Offerings
Table 21. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 22. NeuroVia, Inc. Corporate Summary
Table 23. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 24. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 25. Orpheris, Inc. Corporate Summary
Table 26. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 27. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 28. Minoryx Corporate Summary
Table 29. Minoryx Adrenoleukodystrophy Drugs Product Offerings
Table 30. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 31. MedDay Pharmaceuticals Corporate Summary
Table 32. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Offerings
Table 33. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 34. Adrenoleukodystrophy Drugs Production Capacity (K Units) of Local Manufacturers in France, 2015-2020
Table 35. Adrenoleukodystrophy Drugs Production (K Units) of Local Manufacturers in France, 2015-2020
Table 36. France Adrenoleukodystrophy Drugs Production Market Share of Local Manufacturers, 2015-2020
Table 37. Adrenoleukodystrophy Drugs Production Value (US$, Mn) of Local Manufacturers in France, 2015-2020
Table 38. France Adrenoleukodystrophy Drugs Production Value Market Share of Local Manufacturers, 2015-2020
Table 39. The Percentage of Adrenoleukodystrophy Drugs Production Sold in France and Sold Other Than France by Manufacturers
Table 40. The Percentage of Adrenoleukodystrophy Drugs Production Sold in France and Sold Other Than France by Manufacturers
Table 41. Dangeguojia Adrenoleukodystrophy Drugs Sales (Consumption), Production, Export and Import, 2015-2020
Table 42. Raw Materials and Suppliers
Table 43. Adrenoleukodystrophy Drugs Downstream Clients in France
Table 44. Adrenoleukodystrophy Drugs Distributors and Sales Agents in France

List Of Figures

LIST OF FIGURES

Figure 1. Adrenoleukodystrophy Drugs Segment by Type
Figure 2. Adrenoleukodystrophy Drugs Segment by Application
Figure 3. Dangeguojia Adrenoleukodystrophy Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Adrenoleukodystrophy Drugs Market Size in France, (US$, Mn) & (K Units): 2020 VS 2026
Figure 6. France Adrenoleukodystrophy Drugs Revenue, 2015-2026 (US$, Mn)
Figure 7. Adrenoleukodystrophy Drugs Sales in France: 2015-2026 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2019
Figure 9. By Type - France Adrenoleukodystrophy Drugs Incremental Growth, (US$, Mn), 2015-2026
Figure 10. By Type - France Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 11. By Type - France Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 12. By Type - France Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 13. By Application - Adrenoleukodystrophy Drugs Revenue in France (US$, Mn), 2020 & 2026
Figure 14. By Application - France Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 15. By Application - France Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 16. By Application -France Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 17. France Adrenoleukodystrophy Drugs Production Capacity (K Units), 2015-2026
Figure 18. France Adrenoleukodystrophy Drugs Actual Output (K Units), 2015-2026
Figure 19. France Adrenoleukodystrophy Drugs Production Value (US$, Mn), 2015-2026
Figure 20. The Percentage of France Adrenoleukodystrophy Drugs Export Destination, 2019
Figure 21. The Source of Imports of France Adrenoleukodystrophy Drugs, 2019
Figure 22. PEST Analysis for France Adrenoleukodystrophy Drugs Market in 2020
Figure 23. Adrenoleukodystrophy Drugs Market Opportunities & Trends in France
Figure 24. Adrenoleukodystrophy Drugs Market Drivers in France
Figure 25. Adrenoleukodystrophy Drugs Market Restraints in France
Figure 26. Adrenoleukodystrophy Drugs Industry Value Chain